News for Medicenna Therapeutics Corp. (MDNA.TO)

– Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) KEYTRUDA® (pembrolizum…

**media[532699]**

Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving lon

**media[491435]**

70-year-old patient with advanced chemo-refractory anal cancer achieves complete response (CR) in 8 weeks when treated with MDNA11 in combination with Merck's (

Medicenna to present updated ABILITY-1 study data

TORONTO and HOUSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) — Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immu…

MDNA11 shows significant survival benefits in preclinical glioblastoma models, expanding CD8+ T and NK cells Bizaxofusp selectively targets human tumor cells

**media[467226]**

Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update

NEW YORK, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the securities of Genesis Growth Tech Acquisition...

Gainers

Out of the thousands of stocks that are traded on public markets and are available to retail investors, penny stocks rank right at the top of the list of favorites.